lobbying_activities: 1273662
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1273662 | fc77c288-0941-4bf5-94bc-508a3a1f4944 | Q2 | THE DUBERSTEIN GROUP INC. | 12675 | PFIZER INC. | 2012 | second_quarter | PHA | Drug shortages - Proposed legislation re these issues. Opiate abuse - HR 1316, Stop Oxy Abuse Act of 2011; HR 2119, Ryan Creedon Act of 2011; HR 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011; HR 1065, Pill Mill Crackdown Act of 2011; S 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; Executive Branch action re this issue. Pharmaceutical issues, including tracking and tracing medicines, fostering competition between generic and brand-name pharmaceutical manufacturers - HR 5651, Food and Drug Administration Reform Act of 2012; S 3187, Food and Drug Administration Safety and Innovation Act. Incentives to develop antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011. Establish criminal penalties for trafficking in counterfeit drugs - HR 3468, Counterfeit Drug Penalty Enhancement Act of 2011; S 1886, Counterfeit Drug Penalty Enhancement Act of 2011. National Center for Advancing Transformational Sciences at FDA; agreement to review compounds for potential new uses - Executive Branch actions re these issues. *Follow-on biologics generally. *Certified Importer Program. *Drug safety - HR 1483, Drug Safety Enhancement Act of 2011. | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 100000 | 0 | 0 | 2012-07-19T11:47:19.007000-04:00 |